View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
April 1, 2022

ARCA biopharma announces Phase IIb Covid-19 therapy trial data

In the trial, both the tested doses of rNAPc2 demonstrated to be well-tolerated.

ARCA biopharma has reported topline results from Phase IIb ASPEN-COVID-19 clinical trial of its therapy rNAPc2 (AB201) to potentially treat hospitalised Covid-19 patients. 

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

A highly selective tissue factor inhibitor, rNAPc2 has anti-inflammatory, anticoagulant and potential antiviral effects.

The multicentre, randomised trial assessed two doses of rNAPc2 versus standard of care of heparin in 160 Covid-19 patients in hospital with increased D-dimer levels. 

A biomarker, D-dimer is utilised to evaluate coagulation activation, which is usually raised in hospitalised Covid-19 patients and is linked to adverse clinical outcomes. 

Heparin is an anticoagulant administered to hospitalised Covid-19 patients in the US.

The variation in D-dimer level from baseline to day eight versus heparin is the primary endpoint of the trial. 

The company concluded subject enrolment in the trial of rNAPc2 for Covid-19, in December last year.

Findings showed that for the complete cohort of Covid-19 patients in the hospital setting, the pooled lower and higher rNAPc2 dose arms showed a decline compared to baseline in D-dimer levels of 16.8% versus 11.2% in the heparin arm.

Even though both doses showed a treatment benefit in trial subjects, none of the doses attained statistical significance for the primary efficacy endpoint versus heparin.

Variation in D-dimer levels from baseline at day eight in the per protocol analysis showed a decline of 28.7% in the rNAPc2 dose pooled group versus a rise of 1.1% in subjects who received heparin.

Assessment on an adapted WHO COVID-19 Severity Scale showed that the D-dimer levels reduced from baseline in mild patients but rose in severe patients in the heparin group while no changes were reported in the rNAPc2 arms.

A numerical imbalance favouring rNAPc2 treatment, which was not significant, was reported on the secondary endpoints assessing thrombotic events and time-to-recovery.

In addition, rNAPc2 was demonstrated to be well-tolerated at both the tested doses without any serious treatment-associated adverse events noted.

ARCA biopharma president and CEO Dr Michael Bristow said: “At this time, ARCA is not planning further clinical development of rNAPc2 in Covid-19 in a direct superiority comparison to heparin design. 

“However, we believe the safety margin and apparent efficacy at the lower dose would not preclude a study design evaluating a prophylactic heparin-rNAPc2 combination.”

Related Companies

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU